placebo + iv sildenafil
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Hypertension, Familial Persistent, of the Newborn
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Trial Timeline
Aug 5, 2013 → Sep 28, 2020
NCT ID
NCT01720524About placebo + iv sildenafil
placebo + iv sildenafil is a phase 3 stage product being developed by Pfizer for Pulmonary Hypertension, Familial Persistent, of the Newborn. The current trial status is completed. This product is registered under clinical trial identifier NCT01720524. Target conditions include Pulmonary Hypertension, Familial Persistent, of the Newborn.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01720524 | Phase 3 | Completed |
Competing Products
20 competing products in Pulmonary Hypertension, Familial Persistent, of the Newborn